RIL
ITOS

Rothschild Investment LLC’s iTeos Therapeutics ITOS Stock Holding History

Rothschild Investment LLC’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed -$255 – 3008
2024
Q3 		$255 Buy
25
+15
+150% +$229 ﹤0.01% 2657
2024
Q2 		$148 Buy
+10
New +$143 ﹤0.01% 2577

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Rothschild Investment LLC's ITOS Position: Q4 2024 in Review

Rothschild Investment LLC sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 25 shares — an estimated $255 sold.

Rothschild Investment LLC first reported a position in ITOS in Q2 2024 and held it in 2 quarters. The position peaked at $255 in Q3 2024. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Rothschild Investment LLC reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rothschild Investment LLC sold 25 iTeos Therapeutics shares in Q4 2024, an estimated $255.
  • Rothschild Investment LLC first reported a position in iTeos Therapeutics in Q2 2024 and held it in 2 quarters.
  • Rothschild Investment LLC's iTeos Therapeutics position peaked at $255 in Q3 2024.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Rothschild Investment LLC's 13F filing for Q4 2024, filed 4 Feb 2025.